NASDAQ: BBIO · Life Sciences · 6 alerts · CIK 1743881
Share price
$77.36Close, Nov 16
Market cap
$15.1B
Shares outstanding
194.8MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BridgeBio Pharma, Inc. filings on SEC EDGAR ↗
BridgeBio Pharma CAO Maricel Apuli Sells $146K of Stock
Maricel Apuli, CAO, sold 2,000 shares of BridgeBio Pharma, Inc. at $72.85 a share, worth $146K in total on Oct 30, 2026. Shares held after the trade: 120,687 (-1.6%).
BridgeBio is transitioning to a multi-product commercial stage company with $253.2M in Acaramidus revenue and three major FDA PDUFA dates scheduled within the next seven months.
BridgeBio Pharma reported a significant increase in total revenues to $791.4 million for the first nine months of 2026, driven primarily by net product revenue from Attruby and Beyonttra. Despite the revenue growth, the company maintained a net loss of $382.9 million due to high research and development and selling expenses, though this was an improvement from the $538.3 million loss in the prior year period.
BridgeBio Pharma reported Q3 2026 financial results, highlighted by $353.2 million in total revenue, including $253.2 million from U.S. Attruby net product sales. The company is preparing for three potential product launches in 2026 and 2027 for BBP-418, oral infigratinib, and encaleret, all of which have been granted Priority Review by the FDA.